UCB Announces US FDA Approval of RYSTIGGO^® for the Treatment of Adults with Generalized Myasthenia Gravis

RYSTIGGO® injection for subcutaneous infusion is a humanized IgG4 monoclonal antibody that binds to the neonatal Fc receptor, resulting in the reduction of circulating IgG.1,4. It is the only FDA-approved treatment in adults for both anti-acetylcholine receptor andanti-muscle-specific tyrosine kinase antibody-positive generalized myasthenia gravis.